Amalgamated Bank Supernus Pharmaceuticals, Inc. Transaction History

Amalgamated Bank

$11.7 Billion
Q1 2025

A detailed history of Amalgamated Bank transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Amalgamated Bank holds 15,565 shares of SUPN stock, worth $517,847. This represents 0.0% of its overall portfolio holdings.

Number of Shares

15,565

Previous 16,119 3.44%

Holding current value

$517,847

Previous $583,000 12.52%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 Apr 25, 2025	SELL	$31.17 - $40.0 $17,268 - $22,160	-554 Reduced 3.44%	15,565 $510,000
Q4 2024 Feb 04, 2025	BUY	$31.89 - $37.83 $95 - $113	3 Added 0.02%	16,119 $583,000
Q3 2024 Oct 30, 2024	SELL	$25.77 - $35.16 $6,700 - $9,141	-260 Reduced 1.59%	16,116 $502,000
Q2 2024 Aug 12, 2024	SELL	$25.99 - $33.85 $11,461 - $14,927	-441 Reduced 2.62%	16,376 $438,000
Q1 2024 Apr 23, 2024	SELL	$27.11 - $35.17 $164,259 - $213,095	-6,059 Reduced 26.49%	16,817 $574,000
Q4 2023 Feb 06, 2024	SELL	$22.72 - $29.68 $11,473 - $14,988	-505 Reduced 2.16%	22,876 $662,000
Q3 2023 Nov 08, 2023	SELL	$27.57 - $32.91 $18,554 - $22,148	-673 Reduced 2.8%	23,381 $645,000
Q2 2023 Aug 11, 2023	BUY	$29.91 - $38.73 $54,496 - $70,566	1,822 Added 8.2%	24,054 $723,000
Q1 2023 May 02, 2023	SELL	$34.93 - $42.03 $63,607 - $76,536	-1,821 Reduced 7.57%	22,232 $805,000
Q4 2022 Feb 10, 2023	BUY	$31.09 - $37.88 $12,933 - $15,758	416 Added 1.76%	24,053 $858,000
Q3 2022 Nov 09, 2022	BUY	$28.79 - $35.41 $5,412 - $6,657	188 Added 0.8%	23,637 $800,000
Q2 2022 Aug 15, 2022	BUY	$25.33 - $34.25 $1,773 - $2,397	70 Added 0.3%	23,449 $678,000
Q1 2022 Jun 30, 2022	SELL	$28.51 - $32.9 $33,271 - $38,394	-1,167 Reduced 4.75%	23,379 $756,000
Q4 2021 Feb 15, 2022	SELL	$26.37 - $34.22 $15,637 - $20,292	-593 Reduced 2.36%	24,546 $716,000
Q3 2021 Oct 29, 2021	SELL	$23.54 - $31.39 $11,181 - $14,910	-475 Reduced 1.85%	25,139 $670,000
Q2 2021 Aug 16, 2021	BUY	$26.72 - $33.19 $684,406 - $850,128	25,614 New	25,614 $789,000
Q1 2020 May 13, 2020	SELL	$14.45 - $24.69 $135,526 - $231,567	-9,379 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$19.93 - $29.13 $2,331 - $3,408	117 Added 1.26%	9,379 $222,000
Q3 2019 Nov 13, 2019	SELL	$25.47 - $33.37 $2,394 - $3,136	-94 Reduced 1.0%	9,262 $255,000
Q2 2019 Aug 14, 2019	BUY	$29.96 - $38.87 $43,681 - $56,672	1,458 Added 18.46%	9,356 $310,000
Q1 2019 May 15, 2019	BUY	$32.77 - $41.99 $5,833 - $7,474	178 Added 2.31%	7,898 $277,000
Q4 2018 Feb 15, 2019	BUY	$30.84 - $49.51 $238,084 - $382,217	7,720 New	7,720 $256,000
Q3 2018 Nov 14, 2018	SELL	$42.7 - $56.55 $341,898 - $452,795	-8,007 Closed	0 $0
Q2 2018 Jul 18, 2018	BUY	$44.1 - $59.85 $45,334 - $61,525	1,028 Added 14.73%	8,007 $479,000
Q1 2018 May 22, 2018	SELL	$37.15 - $46.9 $3,826 - $4,830	-103 Reduced 1.45%	6,979 $320,000
Q4 2017 Feb 13, 2018	BUY	$36.4 - $42.6 $19,765 - $23,131	543 Added 8.3%	7,082 $282,000
Q3 2017 Nov 09, 2017	BUY	$36.75 - $49.65 $240,308 - $324,661	6,539	6,539 $262,000

Others Institutions Holding SUPN

# of Institutions

305

Shares Held

60.8M

Call Options Held

8.8K

Put Options Held

6.3K

View Full List

About SUPERNUS PHARMACEUTICALS, INC.

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.78B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

More about SUPN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Amalgamated Bank, based on Form 13F filings with the SEC.

News

Stay updated on Amalgamated Bank with notifications on news.

Account

Amalgamated Bank Supernus Pharmaceuticals, Inc. Transaction History